PSICHE-EROS: ProSpectic Italian Laparoscopic Hybrid mEsh hErnia Repair in Obese patientS Trials

Sponsor
Azienda Sanitaria Locale Napoli 2 Nord (Other)
Overall Status
Recruiting
CT.gov ID
NCT05632952
Collaborator
(none)
120
1
14
8.6

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate safety and effectiveness of a hybrid mesh (GORE® SYNECOR Intraperitoneal Biomaterial) in patients with a BMI of 30 kg/m2 or more undergoing laparoscopic ventral hernia repair (LVHR) with intraperitoneal position of the mesh.

Condition or Disease Intervention/Treatment Phase
  • Device: Intraperitoneal Onlay Mesh positioning Plus

Detailed Description

A prospective Italian multicenter observational trial will be conducted in 8 different Italian centers to compare the effectiveness and feasibility of treatment of Incisional Hernia with GORE® SYNECOR Intraperitoneal Biomaterial mesh in patients with BMI >30 kg/m2. This study was reviewed and approved by the local regional Ethics Committee. The study adhered to the CONSORT guidelines in reporting this trial's results

Study Design

Study Type:
Observational
Anticipated Enrollment :
120 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Laparoscopic Ventral Hernia Repair in Obese Patients: Safe and Effective Use of a Hybrid (PTFE / Biosynthetic) Mesh. Results of a Multicentric Prospective Trial.
Actual Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Jan 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
A

120 patients affected by Incisional Hernia with size between 3 to 10 cm, undergoing Intraperitoneal Onlay Mesh with the closure of defect

Device: Intraperitoneal Onlay Mesh positioning Plus
Intraperitoneal Onlay Mesh (IPOM) Plus with closure of the hernia defect will be performed according to the common recommendations. The closure of the wall defect will be decided according to the surgeon evaluations: hernia size and choice of technique will be recorded in the database. The mesh will have an overlap of at least 5 cm on all sides of the defect. Dimension of the mesh will be sized to overlap the hernia orifice by at least five centimetres and placed in the intraperitoneal position. Using non-articulating laparoscopic fixation devices, 5.1-mm non-absorbable or absorbable tacks will be then positioned around the circumference of the prosthesis in a 3-row manner or 2-row manner based on the intraoperative findings, the patient's specific situation and the operating surgeon's decision.
Other Names:
  • IPOM plus
  • Outcome Measures

    Primary Outcome Measures

    1. Rate of Incisional Hernia at Clinical examination [Patients are postoperatively examined at 1 months.]

      Clinical examination: Incisional Hernia is clinically defined as any visible or palpable ''blowout'' in site of incisional hernia treated

    2. Rate of Incisional Hernia at Clinical examination [Patients are postoperatively examined at 3 months.]

      Clinical examination: Incisional Hernia is clinically defined as any visible or palpable ''blowout'' in site of incisional hernia treated

    3. Rate of Incisional Hernia at Clinical examination [Patients are postoperatively examined at 6 months.]

      Clinical examination: Incisional Hernia is clinically defined as any visible or palpable ''blowout'' in site of incisional hernia treated

    4. Rate of Incisional Hernia at Clinical examination [Patients are postoperatively examined at 12 months.]

      Clinical examination: Incisional Hernia is clinically defined as any visible or palpable ''blowout'' in site of incisional hernia treated

    5. Rate of Incisional Hernia at Clinical examination [Patients are postoperatively examined at 24 months.]

      Clinical examination: Incisional Hernia is clinically defined as any visible or palpable ''blowout'' in site of incisional hernia treated

    6. Rate of Incisional Hernia at Clinical examination [Patients are postoperatively examined at 36 months.]

      Clinical examination: Incisional Hernia is clinically defined as any visible or palpable ''blowout'' in site of incisional hernia treated

    7. Rate of Incisional Hernia at ultrasonographic examination [Patients are postoperatively examined at 1 months.]

      An abdominal ultrasonography with the patient lying prone, will be performed in in all patients (symptomatic or asymptomatic) providing any valuable information about Hernia Recurrence onset. Valsalva maneuver will be performed during the ultrasonography scan. Size and location of all imaging detected Hernia Recurrence will be recorded, as well as any other patient's complaint.

    8. Rate of Incisional Hernia at ultrasonographic examination [Patients are postoperatively examined at 3 months.]

      An abdominal ultrasonography with the patient lying prone, will be performed in in all patients (symptomatic or asymptomatic) providing any valuable information about Hernia Recurrence onset. Valsalva maneuver will be performed during the ultrasonography scan. Size and location of all imaging detected Hernia Recurrence will be recorded, as well as any other patient's complaint.

    9. Rate of Incisional Hernia at ultrasonographic examination [Patients are postoperatively examined at 6 months.]

      An abdominal ultrasonography with the patient lying prone, will be performed in in all patients (symptomatic or asymptomatic) providing any valuable information about Hernia Recurrence onset. Valsalva maneuver will be performed during the ultrasonography scan. Size and location of all imaging detected Hernia Recurrence will be recorded, as well as any other patient's complaint.

    10. Rate of Incisional Hernia at ultrasonographic examination [Patients are postoperatively examined at 12 months.]

      An abdominal ultrasonography with the patient lying prone, will be performed in in all patients (symptomatic or asymptomatic) providing any valuable information about Hernia Recurrence onset. Valsalva maneuver will be performed during the ultrasonography scan. Size and location of all imaging detected Hernia Recurrence will be recorded, as well as any other patient's complaint.

    11. Rate of Incisional Hernia at ultrasonographic examination [Patients are postoperatively examined at 24 months.]

      An abdominal ultrasonography with the patient lying prone, will be performed in in all patients (symptomatic or asymptomatic) providing any valuable information about Hernia Recurrence onset. Valsalva maneuver will be performed during the ultrasonography scan. Size and location of all imaging detected Hernia Recurrence will be recorded, as well as any other patient's complaint.

    12. Rate of Incisional Hernia at ultrasonographic examination [Patients are postoperatively examined at 36 months.]

      An abdominal ultrasonography with the patient lying prone, will be performed in in all patients (symptomatic or asymptomatic) providing any valuable information about Hernia Recurrence onset. Valsalva maneuver will be performed during the ultrasonography scan. Size and location of all imaging detected Hernia Recurrence will be recorded, as well as any other patient's complaint.

    Secondary Outcome Measures

    1. Number of patients affected by Superficial surgical site infections [Within 30 days postoperatively]

      Superficial infections according to Clavien-Dindo criteria

    2. Number of patients affected by Deep surgical site infections [Within 30 days postoperatively]

      Deep surgical site infections according to Clavien-Dindo criteria

    3. Number of patients affected by organ space infections [Within 30 days postoperatively]

      Organ space infections according to Clavien-Dindo criteria

    4. Number of patients affected by Surgical Site Occurence [Within 30 days postoperatively]

      Surgical Site Occurence Reported according to the Ventral Hernia Working Group (VHWG) definitions

    5. Postoperative pain [Postoperative pain will be recorded according to visual analogue scale Visual Analogue Scale at 1 month.]

      Postoperative pain will be recorded according to the Visual Analogue Scale (VAS). The Visual Analogue Scale (VAS) measures pain intensity. The Visual Analogue Scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    6. Postoperative pain [Postoperative pain will be recorded according to visual analogue scale at 12 months.]

      Postoperative pain will be recorded according to the Visual Analogue Scale (VAS). The Visual Analogue Scale (VAS) measures pain intensity. The Visual Analogue Scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    7. Postoperative pain [Postoperative pain will be recorded according to visual analogue scale at 24 months.]

      Postoperative pain will be recorded according to the Visual Analogue Scale (VAS). The Visual Analogue Scale (VAS) measures pain intensity. The Visual Analogue Scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • age > 18 years

    • Clean wounds

    • Informed consent

    • Patients affected by Incisional and Ventral Hernia

    • Elective surgery

    • Hernia size between 3 e 7 cm

    • BMI > 30 kg/m2

    Exclusion Criteria:
    • age < 18 years;

    • Life expectancy < 24 months (as estimated by the operating surgeon), -

    • Pregnancy

    • Immunosuppressant therapy within 2 weeks before surgery

    • Clean-contaminated and contaminated, dirty wounds

    • Cirrhosis

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Francdesco Pizza Napoli Naples Italy 80035

    Sponsors and Collaborators

    • Azienda Sanitaria Locale Napoli 2 Nord

    Investigators

    • Principal Investigator: Francesco Pizza, MD, PhD, Azienda Sanitaria Locale Napoli 2 Nord

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Francesco Pizza, PhD, Md, Azienda Sanitaria Locale Napoli 2 Nord
    ClinicalTrials.gov Identifier:
    NCT05632952
    Other Study ID Numbers:
    • 419N.Reg 26-2022oss
    First Posted:
    Dec 1, 2022
    Last Update Posted:
    Dec 2, 2022
    Last Verified:
    Nov 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Francesco Pizza, PhD, Md, Azienda Sanitaria Locale Napoli 2 Nord
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 2, 2022